Exclusive: Barty Medical Secures Tens-of-Millions-Yuan Extended D-Round Backed by CICC Capital Fund

Recently, Zhejiang Barty Medical Technology Co., Ltd. (hereinafter referred to as “Barty Medical”) announced the completion of a tens-of-millions-yuan expanded financing in its Series D round, invested by funds under CICC Capital.

This represents another strong vote of confidence from the capital market following the company’s completion of a large-scale Series D financing round earlier this year, marking a milestone achievement for Barty Medical in 2026.

In July, the company's independently developed excipient-free drug-coated balloons for coronary and peripheral arteries received EU MDR Class III CE certification, becoming The first drug-coated balloon products globally to gain market access under the European Union’s latest Medical Device Regulation.

The EU MDR is one of the regulatory systems with the highest global market access standards, and this certification marks the dual recognition of Barty’s drug-coating technology by leading global regulatory authorities and developed European markets.

July, Barty and Mozarc(Mozarc Medical, formerly Medtronic’s Renal Health Solutions business unit, jointly controlled by Medtronic and the DaVita Group) signed a Global Strategic Cooperation Agreement to Jointly Forge a New International Landscape in Nephrology

In the same month, through its strategic cooperation with Micro-Energy Medical, Barty Medical obtained exclusive national agency rights for the full range of varicose vein laser ablation products, marking another key move in its peripheral vascular intervention solutions matrix.

The World’s First Matrix Crush™ Coronary Constrained Drug-Coated Balloon, has completed enrollment in the registrational clinical trial jointly led by the team of Academician Ge Junbo from Zhongshan Hospital Affiliated to Fudan University and the team of Academician Wang Jian'an from The Second Affiliated Hospital of Zhejiang University School of Medicine, and will be Completed follow-up within.

As The world’s first third-generation drug-coated balloon benchmarked against the gold-standard therapy, which is expected to revolutionize the preferred treatment regimen for 70% of coronary intervention procedures after its market launch. Addressing the "intervention without implantation" needs of over 10 million coronary heart disease patients in China.

The intensive achievement of milestones stems from a solid foundation. China's First Third-Generation Vascular Interventional Balloon: Matrix Super PTX^®Peripheral Constrained Drug-Coated Balloons Have Rapidly Entered Hundreds of Clinical Centers Across China, with the average monthly implantation volume continuing to grow; all product lines successfully won bids in national and alliance-led centralized procurement programs, with a 100% success rate.

Among them, Heety^®The disposable catheter sheath kit won first place in the 27-province alliance centralized procurement, firmly securing the top position among domestic brands; the products are exported to more than 40 countries and regions worldwide, with the proportion of overseas revenue continuously increasing.

The proceeds from this fundraising round will be primarily used for the commercial promotion and accumulation of clinical evidence for third-generation constrained drug-coated balloons, international cooperation and global clinical data accumulation, as well as the development of subsequent innovative pipelines, further accelerating the globalization of the Barty brand and innovative technologies.

From winning bids in centralized procurement to breaking through the MDR barrier, and from pioneering first-in-class pipelines to partnering with international giants, Barty Medical is driven by the dual engines of “lean manufacturing + innovation leadership.” It has evolved from a domestic alternative in vascular intervention into a Chinese innovative force on the global stage. Let medical technology illuminate the light of life.